Latest Financial Guidance News

Resonance Health has revealed ambitious growth plans at its 2025 AGM, projecting revenue to nearly quadruple by FY26 while maintaining positive EBITDA guidance. The company is broadening its global footprint and diversifying its clinical trial services across multiple therapeutic areas.

Lycopodium Limited projects steady growth for FY26 with revenue guidance of $390-$410 million, underpinned by strong project momentum and the strategic SAXUM acquisition expanding its footprint in the Americas.

Inghams Group reports stable volumes and improved wholesale pricing in early FY26 but faces higher operational costs impacting first-half earnings. A leadership restructure aims to cut costs and boost accountability as the company reaffirms its full-year EBITDA guidance.

Megaport Limited has announced a fully underwritten A$200 million equity raising to fund its acquisition of Latitude.sh, a global Compute-as-a-Service platform, alongside a strategic investment to accelerate network expansion in India. The acquisition is expected to significantly enhance Megaport’s revenue and EBITDA on a pro forma basis for FY25.

Atomos Limited has upgraded its FY26 earnings guidance, forecasting significant sales growth and a return to EBITDA profitability driven by strong demand and a revamped sales strategy.

Iress launches a comprehensive FY26 business efficiency program targeting a 25% cash EBITDA margin, while narrowing its FY25 guidance and welcoming a new CEO.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

Growthpoint Properties Australia kicks off FY26 with robust leasing activity, high occupancy rates, and a strategic $24 million industrial acquisition, maintaining its financial guidance and sustainability credentials.

Austin Engineering has lowered its FY26 revenue and EBIT forecasts due to challenges in key contracts and operational inefficiencies, while outlining strategic measures to restore profitability.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

McPherson’s Limited updates shareholders on its ongoing transformation journey, reporting modest core brand growth in FY25 and outlining a strategic outlook for FY26 focused on sustainable expansion and operational efficiency.

James Hardie confirms key board changes and underscores its commitment to shareholder value amid strong integration progress with AZEK.